直接抗病毒药物在丙型肝炎肝硬化患者中的应用进展  

Advances in the application of direct-acting antivirals in patients with hepatitis C cirrhosis

作　　者：冉锡萍 蔡大川 RAN Xiping;CAI Dachuan(Department of Infectious Diseases,The Second Affiliated Hospital of Chongqing Medical University,Chongqing 401336,China;Key Laboratory of Molecular Biology of Infectious Diseases Designated by the Chinese Ministry of Education,Institute for Viral Hepatitis,Chongqing Medical University,Chongqing 400010,China)

机构地区：[1]重庆医科大学附属第二医院感染病科,重庆401336 [2]感染性疾病分子生物学教育部重点实验室,重庆医科大学病毒性肝炎研究所,重庆400010

出　　处：《临床肝胆病杂志》2024年第8期1682-1687,共6页Journal of Clinical Hepatology

基　　金：重庆市科卫联合医学科研重点项目(2022ZDXM001);重庆市首批公共卫生重点学科(专科)。

摘　　要：慢性丙型肝炎病毒感染可导致肝硬化的发生,肝硬化后出现肝细胞癌等并发症是慢性肝病患者的主要死亡原因。抗病毒治疗可以实现持续病毒学应答,改善肝炎、肝纤维化,进而延缓病程进展。直接抗病毒药物(DAA)在丙型肝炎肝硬化患者中的安全性和有效性已被证实,其是否能改善肝硬化患者疾病并发症和预后逐渐成为讨论和研究的热点。相关数据主要由国外学者报告,我国DAA上市较晚,尚缺乏中远期数据。本文回顾了最新的相关研究,对DAA在丙型肝炎肝硬化患者中的应用现状及其对临床预后的影响进行综述。Chronic hepatitis C virus(HCV)infection can lead to liver cirrhosis,and complications after liver cirrhosis,including hepatocellular carcinoma(HCC),are the leading causes of death in patients with chronic liver diseases.Antiviral therapy can help to realize sustained virologic response,improve hepatitis and liver fibrosis,and delay disease progression.The safety and efficacy of direct-acting antivirals(DAAs)have been confirmed in patients with HCV-related liver cirrhosis,and whether DAAs can improve the complications and prognosis of patients with liver cirrhosis has gradually become a research hotspot.Related data are mainly reported by foreign scholars,and since DAAs have not been marketed in China for a long time,there is still a lack of midand long-term data.This article reviews the latest studies on the application of DAAs in patients with HCV-related liver cirrhosis and the impact of DAAs on clinical prognosis.

关 键 词：肝炎病毒属 肝硬化 直接抗病毒药物 治疗结果 

分 类 号：R512.63[医药卫生—内科学] R575.2[医药卫生—临床医学]